GLUTAMATE DECARBOXYLASE 2
drugOn this page
Also known as Diamyd antigen gad-65Gad-65Gad65Rhgad65Rhugad65
Summary
Glutamate Decarboxylase 2 (CHEMBL4594599) is a phase-3 clinical-stage enzyme; indicated across 2 conditions including type 1 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Enzyme
- Indications: 2 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594599 |
| Name | GLUTAMATE DECARBOXYLASE 2 |
| Type | Enzyme |
| Max phase | 3 |
Also known as: Diamyd antigen gad-65, Gad-65, Gad65, Glutamate decarboxylase 2, Rhgad65, Rhugad65, GLUTAMATE DECARBOXYLASE 2
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00723411 | PHASE3 | TERMINATED | A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU) |
| NCT00751842 | PHASE3 | TERMINATED | A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT |
| NCT00837759 | PHASE2 | TERMINATED | Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: type 1 diabetes mellitus